Company news
Lytix Biopharma Asa (OSL:LYTIX) news
Lytix Biopharma Asa news releases on 6ix. Latest, Aug 18, 2026: Lytix Biopharma Strengthens Business Development Leadership with Appointment of Timothy Herpin…
Press releases & updates
Lytix Biopharma Strengthens Business Development Leadership with Appointment of Timothy Herpin as Chief Business Officer
August 18, 2026
Lytix Biopharma Reports Phase II Data in Melanoma and Triple-Negative Breast Cancer for Ruxotemitide (LTX-315) in Combination with Pembrolizumab
June 1, 2026
Lytix Biopharma : Financial Document (2026 Q1 Lytix Biopharma Quarterly Presentation Final)
May 21, 2026
Lytix Biopharma Q1 2026: Clinical Development Priorities On Track as Registrational Path Planning Advances
May 21, 2026
Lytix Biopharma ASA to Showcase Promising Phase II Results for Ruxotemitide Combination Therapy at ASCO 2026
April 21, 2026
Lytix Biopharma ASA Reports Promising Final Phase II Results for Ruxotemitide (LTX-315) in Combination with Pembrolizumab in PD-1/PD-L1 Refractory Advanced Melanoma
April 21, 2026
Lytix Biopharma : Conversion to public limited liability company and name change registered
April 16, 2026
Lytix Biopharma ASA - Conversion to public limited liability company and name change registered
April 16, 2026
Lytix Biopharma AS: Minutes from Annual General Meeting
April 14, 2026
Lytix Biopharma AS: MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER - GRANT OF SHARE OPTIONS
April 9, 2026
Lytix Biopharma Appoints Renée Christine Amundsen as Chief Operating Officer to Support Next Phase of Growth
April 7, 2026
Lytix Biopharma AS: Notice of Annual General Meeting on 14 April 2026
March 25, 2026
Lytix Biopharma AS: Annual Report for 2025
March 24, 2026
Lytix Biopharma to Present Final Phase II ATLAS-IT-05 Data at the AACR Annual Meeting 2026
March 18, 2026
Lytix Biopharma AS - New share capital registered
February 24, 2026
Lytix Biopharma: Q4 2025 Presentation and Publication of H2 2025 Interim Report
February 12, 2026
Lytix Biopharma : Final result of Subsequent Offering and allocation of Offer Shares
February 10, 2026
Lytix Biopharma: Invitation to Q4 2025 Results Presentation and Publication of H2 2025 Report
February 5, 2026
Lytix Biopharma : New share capital registered
January 14, 2026
Lytix Biopharma : Notice of extraordinary general meeting 26 January 2026
January 12, 2026
Lytix Biopharma Q3 2025: Promising Results Accelerating Development Strategy
November 18, 2025